Tumor Markers

Diagnosis

Tumor Markers and Genetic Markers – Use for Specific Malignancy

The following information is from multiple guideline sources as recommendations for use of tumor markers and genetic markers.

• Gastrointestinal

  Tumor Type	Marker	Recommended Use	Recommending Organizations*
  Hepatic	AFP	Monitoring	ACS, NCCN, ESMO, NACB
  		Early detection in high-risk patients	ACS, NCCN, ESMO, NACB
  	AFP-L3%	Monitoring, early detection in high-risk patients, prognosis	NACB
  	DCP	Monitoring, early detection in high-risk patients, prognosis	NACB
  Gastric	No markers with good evidence	None available	NACB
  	Helicobacter pylori	Environmental risk factor	NCCN
  	E-Cadherin mutations	Risk factor in hereditary forms	NCCN
  Pancreatic (ductal adenocarcinoma)	CA19-9	Monitoring	NCCN, ESMO, NACB
  		Diagnosis	NCCN, NACB
  Colorectal	CEA	Monitoring	ASCO, NACB, ESMO, NCCN
  		Monitoring advanced disease	ASCO, NACB
  		Prognosis	ASCO, ACS, ESMO, NCCN, NACB (if used with other prognostic features)
  	KRAS mutation	Predict response to EGFR inhibitors, prognosis	NCCN, ASCO
  	BRAF V600E	Lynch syndrome risk assessment	NACB
  	MSI/HNPCC (molecular and/or IHC)	Colorectal and Lynch syndrome risk assessment	NCCN, NACB
  	MLH1, MSH2, MSH6, PMS2	Lynch syndrome risk assessment	ESMO, NCCN, NACB
  ACS = American Cancer Society, NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry *Organization also searched: American Gastroenterological Association

• Neuroendocrine

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  All neuroendocrine tumors	Chromogranin A (serum, IHC)	Diagnosis	NCCN, ESMO, NACB
  		Recurrence	NACB
  		Monitoring	NACB
  	Synaptophysin (serum, IHC)	Diagnosis	NCCN
  	Prolactin (serum, IHC)	Diagnosis	NCCN
  	CK (Cytokeratin) (serum)	Diagnosis	NCCN
  	Ki-67 (MIB-1) (IHC)	Diagnosis	NCCN
  Carcinoid	5-HIAA (urine)	Diagnosis	NCCN, ESMO, NACB
  		Monitoring for specific tumor	NCCN, ESMO, NACB
  	Serotonin (serum)	Diagnosis	NACB
  	Chromogranin A (serum, IHC)	Diagnosis and monitoring	NCCN
  	Gastrin (serum, IHC)	Diagnosis and monitoring	NCCN
  	Pancreatic polypeptide (serum, IHC)	Diagnosis and monitoring	NCCN
  Gastrinoma	Gastrin (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  Glucagonoma	Glucagon (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  Pheochromocytoma	Metanephrines (plasma, urine)	Diagnosis and monitoring	NCCN, ESMO, NACB
  	Catecholamines (urine)	Diagnosis and monitoring	NCCN, ESMO, NACB
  Insulinoma	Proinsulin (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  	Insulin (serum, IHC)	Diagnosis and monitoring	NCCN
  	C-peptide (serum, IHC)	Diagnosis and monitoring	NCCN
  Pituitary	Growth hormone (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  	IGF-1 (serum)	Diagnosis and monitoring	NCCN
  	Prolactin (serum, IHC)	Diagnosis and monitoring	NCCN
  	LH/FSH (serum, IHC)	Diagnosis and monitoring	NCCN
  	TSH (serum, IHC)	Diagnosis and monitoring	NCCN
  	Alpha subunit (serum, IHC)	Diagnosis and monitoring	NCCN
  	ACTH (serum, IHC)	Diagnosis and monitoring	NCCN
  VIPoma	VIP (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  Pancreatic neuroendocrine carcinoma	Pancreatic polypeptide (serum, IHC)	Diagnosis and monitoring	NCCN, ESMO, NACB
  	Calcitonin (serum, IHC)	Diagnosis and monitoring	NCCN
  	PTH-related peptide (serum)	Diagnosis and monitoring	NCCN
  	PTH (IHC)	Diagnosis and monitoring	NCCN
  	Somatostatin (serum, IHC)	Diagnosis and monitoring	NCCN
  NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry

• Lung

  Tumor Type	Marker	Recommended Use	Recommending  Organizations*
  Small cell  (SCLC)	NSE (serum, IHC)	Monitoring	ACS, NACB
  		Prognosis	NACB
  	Chromogranin A	Prognosis	NACB
  Non-small cell  (NSCLC)	CEA, SCC Ag	Monitoring, prognosis, detecting relapse	NACB, ASCO
  	CK19 fragment  (CYFRA 21-1),	Prognosis	ASCO
  Mesothelioma	Soluble mesothelin related peptides (Mesomark®)	Monitoring	IMIG, NACB, NCCN
  	CK 5,6	Diagnosis	NCCN
  	CEA	Diagnosis	NCCN
  	b72.3	Diagnosis	NCCN
  	WT-1	Diagnosis	NCCN
  	TTF-1	Diagnosis	NCCN
  	Calretinin	Diagnosis	NCCN
  ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, IMIG = International Mesothelioma Interest Group, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network *Organizations also searched: American Thoracic Society (ATS), British Thoracic Society (BTS), American College of Chest Surgeons (ACCP)

• Female Gynecologic/Genitourinary

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Breast	Estrogen, progesterone receptor (tissue)	Predict hormone response	ASCO, ESMO, NCCN, NACB
  		Prognosis	ASCO (do not use alone), NCCN, NACB (do not use alone), ACS
  	b72.3	Diagnosis	NCCN
  	HER, HER2, HER-2/neu (tissue)	Predict response to Herceptin	ASCO, ESMO, ACS, NCCN, NACB
  		Prognosis	NCCN, NACB
  		Predict response to anthracyclines	ASCO, NCCN, NACB
  	uPA/PAI-1 (tissue)	Prognosis	ASCO, ACS, NACB
  	CA 15-3, CA 27-29	Monitoring advanced disease	ASCO, ESMO, NACB, ACS
  	CEA	Monitoring advanced disease	ASCO, NACB
  	BRCA1, BRCA2	Identifying high-risk patients	ASCO, NCCN, NACB
  	HER-2/neu (serum)	Monitoring, prognosis	NACB
  	p53	Prognosis	NACB
  Cervical	HPV	Risk assessment	NCCN, NACB
  	SCC Ag	Monitoring	NACB
  Ovarian	CA 125	Monitoring	ESMO, NACB, NCCN
  		Differential diagnosis is suspicious pelvic mass	NACB, NCCN
  		Detection of recurrence	ESMO, NACB, NCCN
  		Prognosis	ESMO, NACB
  	βhCG	Diagnosis, recurrence	NCCN
  Gestational trophoblastic	βhCG	Monitoring	ACS, NACB, NCCN
  		Diagnosis	ACS, NACB, NCCN
  Bladder	BTA stat®, BTA TRAK®, NMP22®, UroVysion™, ImmunoCyt™	Monitoring, early detection	ACS, NACB, NCCN
  ASCO = American Society of Clinical Oncology, ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, ACS = American Cancer Society

• Male Genitourinary

  Tumor Type	Marker	Recommended Use	Recommending Organizations*
  Prostate	PSA	Screening	ACS, AUA, EAU, ESMO, NACB, NCCN
  		Staging and prognosis	AUA, EAU, ESMO, NCCN, NACB
  		Monitoring	AUA, EAU, ESMO, NCCN, NACB
  		Follow-up and negative biopsy	NCCN, NACB
  	PCA3	Screening	NACB
  Bladder	BTA stat®, BTA TRAK®, NMP22®, UroVysion™, ImmunoCyt™	Monitoring, diagnosis	ACS, NACB, NCCN
  Germ cell (testicular)	βhCG and AFP	Diagnosis and differential diagnosis of nonseminomatous germ cell cancer of the testes	ASCO, EAU, ESMO, NACB, NCCN
  		Staging and prognosis	ASCO, EAU, ESMO,  NACB, NCCN
  		Monitoring	ASCO, EAU, ESMO, NACB, NCCN
  		Detecting recurrence	ASCO, EAU, ESMO, NACB, NCCN
  	LD	Diagnosis	ASCO, EAU, ESMO, NACB, NCCN
  		Staging and prognosis	ASCO, EAU, ESMO, NACB, NCCN
  		Monitoring	ASCO, EAU, ESMO, NACB, NCCN
  		Detecting recurrence	ASCO, EAU, ESMO, NACB, NCCN
  ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, AUA = American Urological Association, EAU = European Association of Urologists, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

  Brain

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Oligodendroglioma	1p/19q Deletion by FISH	Diagnosis	NACB
  NACB = National Academy of Clinical Biochemistry

  Soft Tissue/Sarcomas

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Ewing sarcoma	EWSR1 – Ewing sarcoma by RT-PCR	Diagnosis	ESMO, NACB, NCCN
  	EWSR1 rearrangement by FISH	Diagnosis	NACB, NCCN
  Synovial	SYT, SYT-SSX	Diagnosis	NACB, NCCN
  	SYT rearrangement by FISH	Diagnosis	NACB, NCCN
  Rhabdomyosarcoma	PAX-FKHR	Diagnosis	NACB, NCCN
  Kaposi sarcoma	HHV8	Diagnosis	NACB, NCCN
  ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

  Lymphoma

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  B-cell and T/NK-cell	IGH/BCL2	Diagnosis and differentiation of lymphomas	NCCN, NACB
  	IGH/CCND1	Diagnosis of mantle cell (MCL) subtype	NCCN, NACB
  	API2-MLT1 t(11;18)	Diagnosis of a subset of MALT lymphomas	NCCN, ESMO, NACB
  	ALK rearrangements	Diagnosis and differentiation	NCCN, NACB
  	c-Myc (MYC rearrangements [t(8;14)])	Diagnosis and differentiation of Burkitt lymphoma	NCCN
  	CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD14, CD15, CD19 (BCL-6), CD20, CD21, CD23, CD33, CD45 (LCA), CD52, CD56, CD57, CD64, CD79a, CD117 (c-KIT), CD138	Diagnosis and differentiation	NCCN, NACB
  	Cyclin D1, SP4 t(11;14)	Diagnosis of MCL and multiple myeloma	NCCN
  	EBV-LMP1, EBV-EBER	Diagnosis and differentiation	NCCN
  	Granzyme B	Diagnosis	NCCN
  	Ki-67 (MIB-1)	Diagnosis	NCCN
  	HTLV	Diagnosis and differentiation	NCCN
  	PAX-5	Diagnosis and differentiation	NCCN
  	TIA-1	Diagnosis and differentiation	NCCN
  	MUM1/IRAF4	Diagnosis and differentiation	NCCN
  NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry

  Leukemia

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  ALL	BCR/ABL1	Diagnosis, prognosis, monitoring	NACB
  	c-Myc (MYC rearrangements [t(8;14)])	Diagnosis and differentiation	NCCN
  	ETV6/RUNX1(TEL/AML1) t(12;21)(p13;q22)	Diagnosis, prognosis, monitoring	NACB
  	E2A/PBX1 t(1;19)(q23;p13.3) (TCF3-PBX1)	Diagnosis, prognosis, monitoring	NACB
  	Hyperdiploidy (+4, +10, +17)	Diagnosis, prognosis, monitoring	NACB
  	MLL rearrangement	Diagnosis, prognosis, monitoring	NACB
  	IGH rearrangement	Diagnosis, prognosis, monitoring	NACB, NCCN
  AML	RUNX1/RUNX1T1 t(8;21)	Diagnosis of prognostically important genetic subtype	ESMO, NACB
  	FLT3-ITD	Prognosis	ESMO, NACB
  	Philadelphia chromosome t(9;22)	Diagnosis and prognosis	NCCN
  	inv(16) or t(16;16) of CBFβ/MYH11	Diagnosis and prognosis	ESMO, NACB, NCCN, WHO
  	AML1/ETO t(8;21)	Diagnosis and prognosis	NCCN, WHO
  	MLLT3-MLL t(9;11)	Prognosis	NCCN
  	c-KIT (CD117)	Prognosis	NCCN
  	NPM1	Prognosis	NCCN
  	CEBPA	Prognosis	NCCN
  	inv(3), t(3;3) EVI1	Prognosis	NCCN
  	DEK/NUP214 t(6;9)(p23;q34)	Prognosis	NCCN
  	PML/RARα , t(15;17)	Diagnosis	ESMO, NACB, NCCN
  	11q23 (MLL)	Prognosis	ESMO, NACB, NCCN
  CLL	ZAP-70	Diagnosis	NCCN, NACB, ESMO
  		Prognosis	ESMO, NACB
  	IgVH mutation	Prognosis	NCCN, ESMO, NACB
  CML	BCR/ABL1	Diagnosis	ESMO, NACB, NCCN
  		Prognosis	NACB, NCCN
  		Monitoring	ESMO, NACB
  	Philadelphia chromosome t(9;22)	Diagnosis and prognosis	NCCN
  ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, WHO = World Health Organization

  Myeloproliferative Neoplasms

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Myeloproliferative	JAK2	Diagnosis	NACB
  Myeloproliferative with associated eosinophilia	PDGFRα, PDGFRβ and FGFR1 rearrangements by FISH	Diagnosis	NACB, WHO
  NACB = National Academy of Clinical Biochemistry, WHO = World Health Organization

  Childhood Tumors

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Neuroblastoma	NSE	Prognosis	NACB
  	N-myc	Prognosis	NACB
  	HVA, VMA, catecholamines	Diagnosis, monitoring	NACB
  Childhood leukemia	MLL-AF4 rearrangement	Diagnosis	NACB
  	BCR/ABL1	Diagnosis, prognosis, monitoring	NACB, NCCN
  	ETV6/RUNX1(TEL/AML1) t(12;21)(p13;q22)	Diagnosis, prognosis, monitoring	NACB, ASCO
  	Hyperdiploidy (+4, +10, +17)	Diagnosis, prognosis, monitoring	NACB
  	MLL-AF4, t(4;11)	Diagnosis, prognosis, monitoring	NACB
  ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

  Skin

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Melanoma	TA90-IC	Monitoring, prognosis	ACS, NACB
  	S-100, HMB45 (gp100)	Diagnosis, usually used in combination	ACS, NACB
  	S-100B (serum)	Monitoring, prognosis	ACS, NACB
  	c-Kit	Response to therapy	ACS
  ACS = American Cancer Society, NACB = National Academy of Clinical Biochemistry

  Head and Neck

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Squamous cell cancers	SCC Ag	Monitoring	NACB
  	CK 19 fragment (CYFRA 21-1)	Prognosis	ASCO
  	HPV	Risk assessment	NACB
  Burkitt lymphoma	EBV-LMP1	Diagnosis	NACB, NCCN
  ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

  Thyroid/Parathyroid

  Tumor Type	Marker	Recommended Use	Recommending Organizations
  Well-differentiated	BRAF V600E (tissue)	Diagnosis	NACB
  	BRAF V600E (serum)	Prognosis	NACB
  	Thyroglobulin (serum)	Diagnosis, monitoring	NCCN, AACE, NACB
  	Thyroglobulin (IHC)	Diagnosis	NACB
  Medullary thyroid carcinoma	Calcitonin	Monitoring, diagnosis	NCCN, AACE, NACB
  	CEA	Diagnosis, monitoring	NCCN, NACB
  Parathyroid	PTH, calcium	Diagnosis, monitoring	NCCN, NACB
  	PTH-related peptide	Diagnosis and monitoring	NCCN
  Hereditary forms	HRPT2	Genetic risk assessment for parathyroid carcinoma or primary hyperparathyroidism	NACB
  	MEN1	Genetic risk assessment for MEN1	AACE, NACB, NCCN
  	RET	Genetic risk assessment for MEN2	AACE, NACB, NCCN
  NCCN = National Comprehensive Cancer Network, AACE = American Association of Clinical Endocrinologists, NACB = National Academy of Clinical Biochemistry

Clinical Background

Tumor and genetic markers may be useful in the diagnosis, treatment, monitoring and prognostication of specific tumors. Available markers include those in the following table (most are available at ARUP^® Laboratories); for recommendations, see the Diagnosis tab. The information that follows is general in nature. For specific information regarding use and interpretation of various markers and tests, consultation with a pathologist is highly advised.

Tumor Markers 

• Tumor markers - #

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  1p/19q, d(1;19)	Oligodendroglioma		T
  5-HIAA	Carcinoid				U
  11q23 (MLL)	Acute lymphocytic leukemia (ALL)	B,T	B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - A

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  AccuDx FDP	Bladder				U
  ACTH	Neuroendocrine			T	B
  AFP	Hepatocellular (HCC), germ cell, ovarian, GI tract			T	B
  AFP-L3%	HCC				B
  ALK rearrangement	Lymphoma, non-small cell lung (NSCLC)1		T	T	T1
  Alpha subunit	Neuroendocrine (pituitary)			T	B
  AML1/ETO t(8;21)	Acute myeloid leukemia (AML)	B,T	T
  API2-MLT1 t(11;18)	Lymphoma, mucosa-associated lymphoid tissue (MALT)	T
  APC	Colorectal	T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - B

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  b72.3	Mesothelioma, lung, breast, ovarian, colon			T
  BF-1	Lymphoma			T
  BG-8 (Lewis Y)	Breast, lung			T	B
  BOB-1	Lymphoma			T
  BRAF V600E	Lynch syndrome, melanoma, thyroid	T
  BTA stat® (Bladder tumor antigen)	Bladder				U
  BTA TRAK®	Bladder				U
  BCR/ABL1 t(9;22)(q34;q11.2)	Chronic myelogenous leukemia (CML), ALL-L1/L2 subtypes	B	B,T		T
  BCL-6 (CD19)	Lymphoma, B-ALL		T	T	B
  bcl-1/JH t(11;14)	Lymphoma	B	T	T	T
  bcl-2/JH t(14;18)	Lymphoma	B	T	T	T
  β-hCG	Trophoblastic, germ cell, lung, melanoma, gastrointestinal, ovarian			T	B
  BRCA1, BRCA2	Breast	B			T
  BRST II (GCDFP-15)	Breast			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - C

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  c-Myc (MYC rearrangements [t(8;14)])	Lymphoma (Burkitt lymphoma), B-ALL	B,T	T	T
  CA 125	Ovarian, cervical, uterine			T	B
  CA 15-3	Breast, pancreatic, lung, ovarian				B
  CA 19-9	Pancreatic, gastric, colon, breast, biliary tract				F
  CA 27.29	Breast				B
  C-peptide	Neuroendocrine				B
  Calcitonin	Neuroendocrine, medullary thyroid carcinoma (MTC)			T	B
  Calcium	Parathyroid				B
  Calretinin	Mesothelioma, lung			T
  Catecholamines	Pheochromocytoma, neuroblastoma				B,U
  CD2	T-ALL, lymphoma			T
  CD3	T-ALL, CLL, lymphoma			T	B
  CD4	Lymphoma			T
  CD5	CLL, lymphoma			T	B
  CD7	Lymphoma			T
  CD8	Lymphoma, bladder			T
  CD10	Lymphoma, ALL			T	B
  CD14 (MY4)	Leukemia/lymphoma			T	B,T
  CD15 (Leu M1)	Lymphoma/leukemia			T	B,T
  CD19 (BCL-6)	Lymphoma, B-ALL		T	T	B
  CD20 (CALLA)	B-ALL, CLL, lymphoma			T	B,T
  CD21	Lymphoma			T
  CD23	CLL, lymphoma			T	B
  CD30 (Ki-1)	Breast			T
  CD33	AML			T	B,T
  CD38	CLL			T	B
  CD45	Lymphoma (DLBL)			T
  CD52	Lymphoma			T
  CD56 (NCAM)	Merkel cell carcinoma (MCC), leukemia/lymphoma			T	B,T
  CD57	Leukemia/lymphoma			T
  CD64	Leukemia/lymphoma			T	B,T
  CD68 (KP1)	Glioma			T
  CD79A	B-ALL			T
  CD95 (APO-1/Fas)	ALL			T
  CD99	ALL, Ewing sarcoma, osteosarcoma			T	B
  CD117 (c-KIT1)	Gastrointestinal stromal tumor (GIST)1, leukemia/lymphoma, melanoma	T1		T1	B
  CD138 (Syndecon-1)	Lymphoma			T
  CD173 (H2)	Breast			T	B
  CD174 (FUT3)	Breast, colorectal, gastric, lung			T	B
  CDX2	Colorectal, ovarian, pancreatic, neuroendocrine (thyroid, parathyroid), gastrointestinal adenocarcinomas, lung, thyroid			T
  CDKN2A	Melanoma	B
  CEA (carcinoembryonic antigen) polyclonal/monoclonal	Colorectal, lung (including NSCLC), breast, ovarian, uterine; MTC, pancreatic1			T	B,F1
  CEACAM1 (17)	Pancreatic				B
  CEBPA	AML	B,T
  Chromogranin A	Neuroendocrine, neuroblastoma, small cell lung (SCLC)			T	B
  CHOP rearrangement	Liposarcoma		T
  CK 5,6	Mesothelioma			T
  CK 7	Colorectal, NSCLC			T
  CK 8,18 (CAM 5.2)	Carcinoid			T
  CK 19 fragment (CYFRA 21-1)	NSCLC, head and neck (squamous cell)				B
  CK 20	Bladder, colorectal, lung			T
  c-KIT (CD117)	Gastrointestinal stromal tumor (GIST)1, leukemia/lymphoma, melanoma	T1		T1	B
  Cyclin D1, SP4 t(11;14)	Lymphoma, CLL		T	T
  Cytokeratin (CK) [pan cytokeratin AE1,3]	Neuroendocrine			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - D

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  DCP (des-gamma-carboxy prothrombin)	HCC				B
  DEK-NUP214 t(6;9)(p23;q34)	AML				B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - E

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  E2A-PBX1 t(1;19)(q23;p13.3) (TCF3-PBX1)	B-ALL	B,T	T
  EBV-LMP1	Burkitt lymphoma, lymphoma/leukemia, head and neck			T
  EBV-EBER	Lymphoma			T
  E-Cadherin	Gastric (familial)			T
  EGFR	Lung, head and neck, colorectal, brain		T	T
  EML4-ALK	NSCLC				T
  Estrogen, progesterone receptors	Breast			T
  ETV6-RUNX1 (TEL-AML1) t(12;21)(p13;q22)	ALL, sarcomas		T
  ETV6-NTRK3 t(12;15)(p13;q25)	Breast cancer	B	B
  EWSR-E1AF t(2;22)(q33;12) EWR1S-ERG t(21;22)(q22;q12) EWS-ETV1 t(7;22)(p22;q12) EWS-ETV4 t(12;22)(q21;q12) EWS-FLI-1 t(11;22)(q24;q12)	Ewing sarcoma	T	T	T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - F

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  FLT3	AML	B,T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - G

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  Gastrin	Gastrinoma, carcinoid			T	B
  Glucagon	Glucagonoma			T	B
  Growth hormone	Neuroendocrine			T	B
  GHRH (growth hormone releasing hormone)	Neuroendocrine (pituitary)				B
  Granzyme B	Lymphoma			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - H

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  βhCG	Trophoblastic, germ cell, lung, melanoma, gastrointestinal, ovarian			T	B
  Hercept/HER2 HER2/neu	Breast	T	T	T	B
  KSHV (HHV8)	Kaposi sarcoma	T		T
  HBME-1 (mesothelial cell)	Mesothelioma			T
  HMB45 (gp100)	Melanoma, ovarian	T		T
  HE4	Ovarian				B
  Helicobacter pylori	Gastric (risk factor)			T
  HPV (hybrid capture on cervical brush1; ISH on tissue2)	Endocervical, head and neck	T1			T2
  HRPT2	Parathyroid, primary hyperparathyroidism			T	B
  HTLV	Lymphoma			T
  HVA	Neuroblastoma				U
  Hyperdiploidy (+4, +10, +17)	ALL		T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - I

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  IGF-1	Neuroendocrine				B
  IGH/BCL2	Lymphoma (follicular cell)		B,T
  IGH-CCND1	Lymphoma (mantle cell), multiple myeloma	B	B,T
  IGH rearrangement	ALL		T
  IL3/IGH t(5;14)(q31;q32)	B-ALL	B,T	T
  ImmunoCyt™/uCyt+™	Bladder				U
  Insulin	Insulinoma			T	B
  inv(3), t(3;3) EVI1	Leukemia	B,T	T
  inv(16) or t(16;16) CBFβ/MYH11	AML	B,T	T
  IGH/myc CEPA t(8;14)	Burkitt lymphoma		T
  IGVH mutation	CLL	B,T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - J

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  JAK2	Myeloproliferative neoplasms	B,T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - K

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  KIT (D816V)	GIST, testicular, melanoma1	B,T,F1			B
  Ki-67 (MIB-1)	Prostate, breast, neuroendocrine, bladder, brain, lymphoma			T
  KRAS mutation detection	Colorectal, breast, pancreatic	T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - L

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  LH/FSH	Neuroendocrine (pituitary)			T	B
  LD	Germ cell, skin				B
  LKB1/STK11	Colorectal	B
  LSA (lipid-associated sialic acid)	Breast, gastrointestinal, lung, leukemia, lymphoma, melanoma, ovarian				B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - M

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  MDM2	Liposarcoma, glioma		T
  Melan A	Melanoma			T
  MEN1, MEN2	Neuroendocrine, parathyroid	B
  Mesomark®	Mesothelioma				B
  Metanephrines	Pheochromocytoma				B,U
  Microsatellite instability (MSI)	Colorectal	B,T	B,T	T
  MLH1, MSH2, MSH6, PMS2	Colorectal, Lynch syndrome	B,T		T
  MLL-AF4 t(4;11)	Infant leukemia	B,T
  MLLT3-MLL t(9;11)	AML, ALL	B,T	T
  MPO (myeloperoxidase)	Breast			T
  Muc-1, Muc-2, Muc-4	Pancreatic, thyroid, biliary			T	B
  MUC-5AC glycoprotein	Pancreatic, cholangiocarcinoma, gastric			T
  MUM1/IRF4	B-cell lymphoma (DLBL)			T
  Myo D-1, myogenin, myoglobin, myosin	Rhabdomyosarcoma			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - N

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  Neurofilament (68kDa)	Brain, lung			T
  NPM1	AML	B,T
  NMP22®	Bladder				U
  N-myc	Neuroblastoma		T
  NPM-ALK/NPM1 (p80)	Lymphoma (anaplastic large cell lymphoma)			T
  NRAS	Colorectal, Lynch syndrome, melanoma	T			T
  NSE	Neuroblastoma, SCLC, neuroendocrine			T	B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - O

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  Oct-2	Lymphomas, breast			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

  Tumor markers - P

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  PAM50	Breast	T
  p16 (INK4/CDKN2)	Bladder	B		T
  p21 (Cip1/Waf1)	Bladder			T
  p27 (Kip1)	Bladder, breast, colon, stomach, lung, pituitary			T
  p53	Breast (deletions occur across most cancers), bladder	B	T	T
  Pancreatic polypeptide	Neuroendocrine, carcinoid			T	B
  Philadelphia chromosome t(9;22)	AML, CML	B,T	T
  PTH (parathyroid hormone)	Neuroendocrine, parathyroid			T	B
  PTH-related peptide	Neuroendocrine, parathyroid				B
  PAX2	High grade tubo-ovarian serous carcinoma, renal cell carcinoma			T
  PAX3-FKHR t(2;13)(q35;q14) PAX7-FKHR t(1;13)(p36;q14)	Rhabdomyosarcoma	T
  PAX3-FOXO4 t(x;2)	Sarcoma		T
  PAX-5	Lymphoma, ALL		T	T
  PAX8-PPARγ1	Thyroid	B
  PCA3	Prostate				B,U
  PDGFRβ, PDGFRα rearrangements, FGFR1, CBFB	GIST, myeloproliferative neoplasms (MPN)		T	T
  PGP 9.5	Carcinoid, nerve-sheath tumor			T
  PIK3CA	Breast, brain, HCC, colon, ovarian, prostate, leukemia	T
  PLAP	Seminoma, germinoma, ovarian			T
  PML-RARα t(15;17)	AML (promyelocytic)		T
  PRCC/TFE3 t(X;1)(p11.2;q21)	Renal cell	B
  Proinsulin	Insulinoma			T	B
  Prolactin	Neuroendocrine (pituitary)			T	B
  PSA	Prostate			T	B
  PTEN	Colorectal	B
  PTH	Parathyroid				B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - R

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  RB-1	Bladder			T
  RET (MEN2a1, MEN2b2)	Neuroendocrine1, parathyroid1, MTC2	B
  RUNX1-RUNX1T1 (AML-ETO)	AML, M2 subtype	B,T	T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - S

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  S-100, S-100B	Melanoma			T	B
  SCC Ag (squamous cell carcinoma antigen)	Head and neck, NSCLC				B
  SKp2	Breast			T
  SMAD4	Colorectal	B
  Serotonin	Carcinoid				B
  Somatostatin	Somatostatinoma			T	B
  Survivin	Bladder			T
  Synaptophysin	Neuroendocrine			T
  SYT-SSX1, STY-SSX2, SYT-SSX4	Synovial sarcoma	T	T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - T

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  TA90-IC	Melanoma			T	B
  t(15;17), t(8;21), t(16;16)	AML	B,T	T
  TCRA, TCRB	T-ALL	B		T
  TdT	ALL			T
  Thyroglobulin	Neuroendocrine (thyroid, parathyroid), thyroid (well-differentiated)		T	T	B,F
  TIA-1	Lymphoma			T
  TMPR SS2-EGR	Prostate	B
  TSH	Neuroendocrine (pituitary), thyroid			T	B
  TTF-1 (thyroid transcription factor)	Thyroid, mesothelioma, sarcoma, adenocarcinoma, neuroendocrine			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - U

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  UGT1A1	Colorectal	B
  uPA/PAI-1	Breast			T
  UroVysion™ (bladder cancer, pancreatobiliary FISH)	Bladder1, pancreatic2		U1 T2
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - V

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  Villin	Adenocarcinoma (pancreatic, gastrointestinal)			T
  VIP	Vasoactive intestinal peptide tumor (VIPoma)			T	B
  VMA	Neuroblastoma				U
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - W

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  WT-1 (Wilms tumor 1)	Ewing sarcoma, myelodysplastic syndrome (MDS), leukemia, mesothelioma, sarcoma, adenocarcinoma			T
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

• Tumor markers - Z

  Marker	Malignancy	Methodology
  		Molecular	FISH	IHC Stain	Other
  ZAP-70	CLL			T	B
  B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid

Indications for Laboratory Testing

• Tests generally appear in the order most useful for common clinical situations
• Click on number for test-specific information in the ARUP Laboratory Test Directory

Gastrointestinal

Test Name and Number	Comments
Alpha Fetoprotein, Serum (Tumor Marker) 0080428 Method: Electrochemiluminescent Immunoassay	HCC tumor marker
PIK3CA Mutation Detection 2004510 Method: Polymerase Chain Reaction/Pyrosequencing	HCC and colorectal tumor marker
Alpha Fetoprotein, Total and L3 Percent Effective Immediately 0081208 Method: Liquid-Phase Binding Immunoassay	Risk assessment for development of HCC in patients with chronic liver diseases
Alpha-1-Fetoprotein (AFP) by Immunohistochemistry 2003436 Method: Immunohistochemistry	Gastrointestinal tumor marker
Des-gamma-carboxy Prothrombin 0081312 Method: Liquid-Phase Binding Immunoassay	Tumor marker for HCC monitoring, prognosis and early detection in high-risk patients
Cancer Antigen-GI (CA 19-9), Body Fluid 0020746 Method: Electrochemiluminescent Immunoassay	Pancreatic cancer tumor marker
Cancer Antigen-GI (CA 19-9) 0080461 Method: Electrochemiluminescent Immunoassay	Tumor marker for pancreatic ductal adenocarcinoma
Pancreatobiliary FISH 2002461 Method: Fluorescence in situ Hybridization/Automated Image Analysis or Manual Screening	Pancreatic cancer tumor marker
Carcinoembryonic Antigen 0080080 Method: Eletrochemiluminescent Immunoassay	Colorectal cancer tumor marker
Gastrointestinal Stromal Tumor Mutation 2002674 Method: Polymerase Chain Reaction/High Resolution Melt Analysis	Determine presence of KIT and PDGFRA mutations
BRAF V600E Mutation with Reflex to MLH1 Promoter Methylation, Paraffin 0051750 Method: Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer Analysis	Lynch syndrome tumor marker
BRAF V600E Mutation Detection by PCR 2002498 Method: Polymerase Chain Reaction/Fluorescence Monitoring	Lynch syndrome tumor marker Predict response to EGFR-directed therapy
Mismatch Repair by IHC 0049302 Method: Immunohistochemistry	Colorectal cancer and Lynch syndrome tumor marker
Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR 0051740 Method: Polymerase Chain Reaction/Fragment Analysis	Lynch syndrome tumor marker
HNPCC/Lynch Syndrome Deletion/Duplication 2001728 Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification	Germline test for Lynch syndrome For PMS2 testing, suspected deletions or duplication in exons 12-15 require sequencing to exclude pseudogene copy number variants
KRAS Mutation Detection 0040248 Method: Polymerase Chain Reaction/Pyrosequencing	Use for therapy with EGFR inhibitors Assay detects mutations in codons 12, 13, and 61
KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection 2001932 Method: Polymerase Chain Reaction/Pyrosequencing/Fluorescence Resonance Energy Transfer	Use for therapy with EGFR inhibitors Assay detects mutations in codons 12, 13, and 61 Detects mutations in codons 12, 13, and 61; if KRAS is not detected, BRAF codon 600 Mutation Detection will be performed
NRAS Mutation Detection by Pyrosequencing 2003123 Method: Polymerase Chain Reaction/Pyrosequencing	Use in metastatic tumors to predict response to EGFR-directed therapy
Carcinoembryonic Antigen, Monoclonal (CEA M) by Immunohistochemistry 2003824 Method: Immunohistochemistry	Gastrointestinal tumor marker
Carcinoembryonic Antigen, Polyclonal (CEA P) by Immunohistochemistry 2003827 Method: Immunohistochemistry	Gastrointestinal tumor marker
E-Cadherin by Immunohistochemistry 2003869 Method: Immunohistochemistry	Gastrointestinal tumor marker
CD117 (c-Kit) by Immunohistochemistry 2003806 Method: Immunohistochemistry	Gastrointestinal tumor marker
Cytokeratin 7 (CK 7) by Immunohistochemistry 2003854 Method: Immunohistochemistry	Gastrointestinal tumor marker
Helicobacter pylori by Immunohistochemistry 2003941 Method: Immunohistochemistry	Risk marker for gastrointestinal cancer
Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920 Method: Immunohistochemistry	Gastrointestinal and pancreatic tumor marker
Villin by Immunohistochemistry 2004178 Method: Immunohistochemistry	Gastrointestinal tumor marker
CDX2 by Immunohistochemistry 2003821 Method: Immunohistochemistry	Gastrointestinal tumor marker
Muc-1 by Immunohistochemistry 2004002 Method: Immunohistochemistry	Gastrointestinal tumor marker
Muc-2 by Immunohistochemistry 2004005 Method: Immunohistochemistry	Gastrointestinal tumor marker
Muc-4 by Immunohistochemistry 2004008 Method: Immunohistochemistry	Gastrointestinal tumor marker
Muc 5AC by Immunohistochemistry 2003999 Method: Immunohistochemistry	Gastrointestinal tumor marker
Breast Carcinoma b72.3 by Immunohistochemistry 2003445 Method: Immunohistochemistry	Gastrointestinal tumor marker
Gastrin by Immunohistochemistry 2003896 Method: Immunohistochemistry	Gastrointestinal tumor marker
p27 (Kip1) by Immunohistochemistry 2004070 Method: Immunohistochemistry	Gastrointestinal tumor marker
Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848 Method: Immunohistochemistry	Gastrointestinal tumor marker
SMAD4 by Immunohistochemistry 2006403 Method: Immunohistochemistry	Gastrointestinal tumor marker

Neuroendocrine

Test Name and Number	Comments
Chromogranin A 0080469 Method: Enzyme Immunoassay	Neuroendocrine cancer tumor marker
Chromogranin A by Immunohistochemistry 2003830 Method: Immunohistochemistry	Neuroendocrine tumor marker
Pan Cytokeratin (AE1,3) by Immunohistochemistry 2003433 Method: Immunohistochemistry	Neuroendocrine tumor marker
ACTH by Immunohistochemistry 2003427 Method: Immunohistochemistry	Neuroendocrine tumor marker
Calcitonin by Immunohistochemistry 2003481 Method: Immunohistochemistry	Neuroendocrine tumor marker
Growth Hormone by Immunohistochemistry 2003929 Method: Immunohistochemistry	Neuroendocrine tumor marker
Insulin by Immunohistochemistry 2003972 Method: Immunohistochemistry	Neuroendocrine tumor marker
Gastrin by Immunohistochemistry 2003896 Method: Immunohistochemistry	Neuroendocrine tumor marker
Glucagon by Immunohistochemistry 2003902 Method: Immunohistochemistry	Neuroendocrine tumor marker
Ki-67 with Interpretation by Immunohistochemistry 2007182 Method: Immunohistochemistry	Neuroendocrine tumor marker
Parathyroid Hormone (PTH) by Immunohistochemistry 2004118 Method: Immunohistochemistry	Neuroendocrine tumor marker
Prolactin by Immunohistochemistry 2004109 Method: Immunohistochemistry	Neuroendocrine tumor marker
Somatostatin by Immunohistochemistry 2004133 Method: Immunohistochemistry	Neuroendocrine tumor marker
Synaptophysin by Immunohistochemistry 2004139 Method: Immunohistochemistry	Neuroendocrine tumor marker
Thyroglobulin by Immunohistochemistry 2004145 Method: Immunohistochemistry	Neuroendocrine tumor marker
Thyroid Transcription Factor (TTF-1) by Immunohistochemistry 2004166 Method: Immunohistochemistry	Neuroendocrine tumor marker
Protein Gene Product (PGP) 9.5 by Immunohistochemistry 2004091 Method: Immunohistochemistry	Carcinoid tumor marker
CDX2 by Immunohistochemistry 2003821 Method: Immunohistochemistry	Pancreatic neuroendocrine tumor marker
Cytokeratin 8,18 Low Molecular Weight (CAM 5.2) by Immunohistochemistry 2003493 Method: Immunohistochemistry	Carcinoid tumor marker
Neuron Specific Enolase, Polyclonal  (NSE P) by Immunohistochemistry 2004052 Method: Immunohistochemistry	Neuroendocrine tumor marker
5-Hydroxyindoleacetic Acid (HIAA), Urine 0080420 Method: High Performance Liquid Chromatography	Carcinoid tumor marker
Serotonin, Serum 0080397 Method: High Performance Liquid Chromatography	Neuroendocrine cancer tumor marker
Serotonin, Whole Blood 0080395 Method: High Performance Liquid Chromatography	Neuroendocrine cancer tumor marker
Gastrin 0070075 Method: Chemiluminescent Immunoassay	Neuroendocrine cancer tumor marker
Glucagon 0099165 Method: Radioimmunoassay	Neuroendocrine cancer tumor marker
Catecholamines Fractionated by LC-MS/MS, Urine Free 0080407 Method: Tandem Mass Spectrometry	Neuroblastoma tumor marker
Proinsulin 0070112 Method: Two-Site Enzyme Immunoassay	Neuroendocrine cancer tumor marker
Homovanillic Acid (HVA), Urine 0080422 Method: High Performance Liquid Chromatography	Neuroblastoma tumor marker
Vanillylmandelic Acid (VMA) & Homovanillic Acid (HVA), Urine 0080470 Method: High Performance Liquid Chromatography	Neuroblastoma tumor marker
Metanephrines, Plasma (Free) 0050184 Method: High Performance Liquid Chromatography	Preferred marker for the diagnosis of pheochromocytoma
Metanephrines Fractionated by HPLC-MS/MS, Urine 2007996 Method: High Performance Liquid Chromatography-Tandem Mass Spectrometry	Pheochromocytoma tumor marker
Proinsulin/Insulin Ratio 0070256 Method: Refer to individual components	Neuroendocrine cancer tumor marker
Vasoactive Intestinal Peptide 0099435 Method: Radioimmunoassay	Neuroendocrine cancer tumor marker
Pancreatic Polypeptide 0099436 Method: Radioimmunoassay	Neuroendocrine cancer tumor marker
Muc-1 by Immunohistochemistry 2004002 Method: Immunohistochemistry	Neuroendocrine tumor marker
Muc-2 by Immunohistochemistry 2004005 Method: Immunohistochemistry	Neuroendocrine tumor marker
Muc-4 by Immunohistochemistry 2004008 Method: Immunohistochemistry	Neuroendocrine tumor marker
Muc 5AC by Immunohistochemistry 2003999 Method: Immunohistochemistry	Neuroendocrine tumor marker

Lung

Test Name and Number	Comments
Neuron Specific Enolase 0098198 Method: Enzyme-Linked Immunosorbent Assay	SCLC tumor marker
Chromogranin A 0080469 Method: Enzyme Immunoassay	SCLC tumor marker
Cytokeratin 19 Fragment (CYFRA 21-1), Serum 0081344 Method: Enzyme-Linked Immunosorbent Assay	SCLC tumor marker
Soluble Mesothelin-Related Peptides (MESOMARK®) 0081284 Method: Enzyme-Linked Immunosorbent Assay	Mesothelioma marker
CDX2 by Immunohistochemistry 2003821 Method: Immunohistochemistry	Lung tumor marker
Cytokeratin 19 (CK 19) by Immunohistochemistry 2003845 Method: Immunohistochemistry	Lung tumor marker
Carcinoembryonic Antigen, Monoclonal (CEA M) by Immunohistochemistry 2003824 Method: Immunohistochemistry	Lung tumor marker
Carcinoembryonic Antigen, Polyclonal (CEA P) by Immunohistochemistry 2003827 Method: Immunohistochemistry	Lung tumor marker
Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry 2003851 Method: Immunohistochemistry	Lung tumor marker
Chromogranin A by Immunohistochemistry 2003830 Method: Immunohistochemistry	Lung tumor marker
Cytokeratin 7 (CK 7) by Immunohistochemistry 2003854 Method: Immunohistochemistry	Lung tumor marker
Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848 Method: Immunohistochemistry	Lung tumor marker
Wilms Tumor (WT-1), N-terminus by Immunohistochemistry 2004184 Method: Immunohistochemistry	Lung tumor marker
Neuron Specific Enolase, Polyclonal  (NSE P) by Immunohistochemistry 2004052 Method: Immunohistochemistry	Lung tumor marker
Neurofilament by Immunohistochemistry 2004049 Method: Immunohistochemistry	Lung tumor marker
Calretinin by Immunohistochemistry 2003490 Method: Immunohistochemistry	Lung tumor marker
Breast Carcinoma b72.3 by Immunohistochemistry 2003445 Method: Immunohistochemistry	Lung tumor marker
p27 (Kip1) by Immunohistochemistry 2004070 Method: Immunohistochemistry	Lung tumor marker
Thyroid Transcription Factor (TTF-1) by Immunohistochemistry 2004166 Method: Immunohistochemistry	Lung tumor marker
Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920 Method: Immunohistochemistry	Lung tumor marker

Female Gynecologic/Genitourinary

Test Name and Number	Comments
ERBB2 (HER2/neu) (4B5) by Immunohistochemistry, Tissue with Reflex to Dual ISH if 2+ 2007782 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) (4B5) by Immunohistochemistry, Tissue with Reflex to FISH if 2+ 2002217 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) (4B5) by Immunohistochemistry, Tissue with Reflex to FISH if 2+ or 3+ 2002216 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) (4B5) with Interpretation by Immunohistochemistry, Tissue 2002218 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) (HerceptTest) with Interpretation by Immunohistochemistry, Tissue 0049174 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) (HercepTest) by Immunohistochemistry, Tissue with Reflex to Dual ISH if 2+ 2007785 Method: Immunohistochemistry	Breast cancer tumor marker (test is graded 0-3 in a semiquantitative manner)
ERBB2 (HER2/neu) Gene Amplification by FISH, Tissue 0049218 Method: Fluorescence in situ Hybridization	Breast cancer tumor marker
ERBB2 (HER2/neu) Gene Amplification by PCR 0049390 Method: Polymerase Chain Reaction	Breast cancer tumor marker
Estrogen/Progesterone Receptor with Interpretation by Immunohistochemistry 0049210 Method: Immunohistochemistry	Breast cancer tumor marker
Carcinoembryonic Antigen, Monoclonal (CEA M) by Immunohistochemistry 2003824 Method: Immunohistochemistry	Breast cancer tumor marker
Carcinoembryonic Antigen, Polyclonal (CEA P) by Immunohistochemistry 2003827 Method: Immunohistochemistry	Breast cancer tumor marker
Placental Alkaline Phosphatase (PLAP) by Immunohistochemistry 2004097 Method: Immunohistochemistry	Breast cancer tumor marker
Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920 Method: Immunohistochemistry	Breast cancer tumor marker
CD30 (Ki-1) by Immunohistochemistry 2003547 Method: Immunohistochemistry	Breast cancer tumor marker
Breast 2 (GCDFP-15) by Immunohistochemistry 2003472 Method: Immunohistochemistry	Breast cancer tumor marker
Cancer Antigen 125 by Immunohistochemistry 2003478 Method: Immunohistochemistry	Breast cancer tumor marker
Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848 Method: Immunohistochemistry	Breast cancer tumor marker
Ki-67 with Interpretation by Immunohistochemistry 2007182 Method: Immunohistochemistry	Breast cancer tumor marker
PIK3CA Mutation Detection 2004510 Method: Polymerase Chain Reaction/Pyrosequencing	Breast cancer tumor marker
Alpha-1-Fetoprotein (AFP) by Immunohistochemistry 2003436 Method: Immunohistochemistry	Germ cell tumor marker
Breast Carcinoma b72.3 by Immunohistochemistry 2003445 Method: Immunohistochemistry	Breast cancer tumor marker
Myeloperoxidase (MPO) by Immunohistochemistry 2004014 Method: Immunohistochemistry	Breast cancer tumor marker
Cancer Antigen-Breast (CA 15-3) 0080464 Method: Electrochemiluminescent Immunoassay	Breast cancer tumor marker
Cancer Antigen 27.29 0080392 Method: Chemiluminescent Immunoassay	Breast cancer tumor marker
Carcinoembryonic Antigen 0080080 Method: Electrochemiluminescent  Immunoassay	Breast cancer tumor marker
HER-2/neu Quantitative by ELISA 2004672 Method: Enzyme-Linked Immunosorbent Assay	Breast cancer tumor marker
p53 with Interpretation by Immunohistochemistry 0049250 Method: Immunohistochemistry	Breast and bladder cancer tumor marker
Cytology, ThinPrep® Pap with Reflex to Human Papillomavirus (HPV) DNA Probe, High Risk 8100212 Method: ThinPrep® 2000 System/Routine Cytopathologic Evaluation/Nucleic Acid Probe	Cytologic screening for cervical cancer and its usual precursor lesions
Squamous Cell Carcinoma Antigen, Serum 0081054 Method: Enzyme-Linked Immunosorbent Assay	Cervical cancer tumor marker
Human Papillomavirus (HPV) DNA Probe, High Risk, Cervical Brush (Digene) 0065999 Method: Nucleic Acid Probe	Cervical cancer tumor marker
Human Papillomavirus (HPV) DNA Probe, High Risk SurePath® (AutoCyte) 0060744 Method: Nucleic Acid Probe	Cervical cancer tumor marker
Human Papillomavirus (HPV) DNA Probe, High Risk (ThinPrep®) 0060750 Method: Nucleic Acid Probe	Cervical cancer tumor marker
Human Papillomavirus (HPV) High Risk in situ Hybridization, Paraffin 2002899 Method: In situ Hybridization	Cervical cancer tumor marker
Cancer Antigen 125 0080462 Method: Electrochemiluminescent Immunoassay	Ovarian cancer tumor marker
Human Epididymis Protein 4 (HE4) 2003020 Method: Enzyme Immunoassay	Ovarian cancer tumor marker
Beta-hCG, Quantitative (Tumor Marker) 0070029 Method: Chemiluminescent Immunoassay	Tumor marker for gestational trophoblastic disease and ovarian cancer
Bladder Tumor Associated Antigen 8100500 Method: Qualitative Immunoassay	Urine-based bladder cancer tumor marker
UroVysion™ FISH 8100600 Method: Fluorescence in situ Hybridization/Automated Image Analysis or Manual Screening	Urine-based bladder cancer molecular genetic test
CDX2 by Immunohistochemistry 2003821 Method: Immunohistochemistry	Tumor marker for breast, ovarian, and uterine cancers
Placental Alkaline Phosphatase (PLAP) by Immunohistochemistry 2004097 Method: Immunohistochemistry	Germ cell (ovarian) tumor marker
p16 by Immunohistochemistry 2004064 Method: Immunohistochemistry	Bladder cancer tumor marker
p21, WAF, CIP1 by Immunohistochemistry 2004067 Method: Immunohistochemistry	Bladder cancer tumor marker
p27 by Immunohistochemistry 2004070 Method: Immunohistochemistry	Bladder cancer tumor marker
CD8 by Immunohistochemistry 2003520 Method: Immunohistochemistry	Bladder cancer tumor marker
PAX2 by Immunohistochemistry 2006291 Method: Immunohistochemistry	Renal cell, high grade tubo-ovarian serous tumor marker

Male Genitourinary

Test Name and Number	Comments
Prostate Specific Antigen, Ultrasensitive 0098581 Method: Electrochemiluminescent Immunoassay	Prostate cancer tumor marker
Prostate Specific Antigen, Total with Reflex to Free PSA (Includes Free Percentage) 0080264 Method: Electrochemiluminescent Immunoassay	Prostate cancer tumor marker
PIK3CA Mutation Detection 2004510 Method:  Polymerase Chain Reaction/Pyrosequencing	Prostate cancer tumor marker
Prostate Specific Antigen, 0070121 Method: Electrochemiluminescent Immunoassay	Marker for recurrence after radical prostatectomy
PCA3 - Prostate Cancer Biomarker 2001999 Method: Transcription-mediated Amplification/ Hybridization Protection Assay	Prostate cancer tumor marker; use if PSA is >10 ng/mL and biopsy negative
Bladder Tumor Associated Antigen 8100500 Method: Qualitative Immunoassay	Urine-based bladder cancer tumor marker
NMP22® 0080281 Method: Enzyme Immunoassay	Male bladder cancer tumor marker
UroVysion™ FISH 8100600 Method: Fluorescence in situ Hybridization/Automated Image Analysis or Manual Screening	Urine-based bladder cancer tumor marker
Beta-hCG, Quantitative (Tumor Marker) 0070029 Method: Chemiluminescent Immunoassay	Testicular cancer (germ cell) tumor marker
Alpha Fetoprotein, Serum (Tumor Marker) 0080428 Method: Electrochemiluminescent Immunoassay	Testicular cancer (germ cell) tumor marker
p53 with Interpretation by Immunohistochemistry 0049250 Method: Immunohistochemistry	Bladder cancer tumor marker
Placental Alkaline Phosphatase (PLAP) by Immunohistochemistry 2004097 Method: Immunohistochemistry	Testicular cancer (germ cell) tumor marker
Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920 Method: Immunohistochemistry	Testicular cancer (germ cell) tumor marker
Ki-67 with Interpretation by Immunohistochemistry 2007182 Method: Immunohistochemistry	Bladder cancer tumor marker
p16 by Immunohistochemistry 2004064 Method: Immunohistochemistry	Bladder cancer tumor marker
p21, WAF, CIP1 by Immunohistochemistry 2004067 Method: Immunohistochemistry	Bladder cancer tumor marker
p27 by Immunohistochemistry 2004070 Method: Immunohistochemistry	Bladder cancer tumor marker
CD8 by Immunohistochemistry 2003520 Method: Immunohistochemistry	Bladder cancer tumor marker
Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848 Method: Immunohistochemistry	Bladder cancer tumor marker
Prostate Specific Antigen by Immunohistochemistry 2004112 Method: Immunohistochemistry	Prostate cancer marker
PAX2 by Immunohistochemistry 2006291 Method: Immunohistochemistry	Renal cell carcinoma marker

Brain

Test Name and Number	Comments
1p/19q Deletion by FISH 0049360 Method: Fluorescence in situ Hybridization	Oligodendroglioma marker
Neurofilament by Immunohistochemistry 2004049 Method: Immunohistochemistry	Brain tumor marker
PIK3CA Mutation Detection 2004510 Method: Polymerase Chain Reaction/Pyrosequencing	Brain tumor marker
CD68, KP1 by Immunohistochemistry 2003598 Method: Immunohistochemistry	Glioma tumor marker

Soft Tissue/Sarcomas

Test Name and Number	Comments
EWSR1 (22q12) Gene Rearrangement by FISH 2007225 Method: Fluorescence in situ Hybridization	Ewing sarcoma tumor marker
SYT-SSX t(X;18) Translocations by RT-PCR 0040114 Method: Reverse Transcription Polymerase Chain Reaction/Fluorescence Monitoring	Sarcomas tumor marker
Kaposi Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 0055629 Method: Polymerase Chain Reaction/Fluorescence Monitoring	Sarcomas tumor marker
Herpes Virus 8 by Immunohistochemistry 2003932 Method: Immunohistochemistry	Kaposi sarcoma tumor marker
Wilms Tumor (WT-1), N-terminus by Immunohistochemistry 2004184 Method: Immunohistochemistry	Sarcomas tumor marker
Myogenin (Myf4) by Immunohistochemistry 2004017 Method: Immunohistochemistry	Rhabdomyosarcoma tumor marker
Myoglobin by Immunohistochemistry 2004031 Method: Immunohistochemistry	Rhabdomyosarcoma tumor marker
Myosin by Immunohistochemistry 2004034 Method: Immunohistochemistry	Rhabdomyosarcoma tumor marker
PAX-FKHR Translocation by RT-PCR 0040113 Method: Reverse Transcription Polymerase Chain Reaction/Fluorescence Monitoring	Rhabdomyosarcoma tumor marker
MDM2 Gene Amplification by FISH 2003016 Method: Fluorescence in situ Hybridization	Sarcomas tumor marker
SS18 (SYT) (18q11) Gene Rearrangement by FISH 2007222 Method: Fluorescence in situ Hybridization	Sarcomas tumor marker
MDM2 by Immunohistochemistry 2005848 Method: Immunohistochemistry	Sarcomas tumor marker

Lymphoma

Test Name and Number	Comments
IGH-BCL2 (BCL-2/JH) Translocation, t(14;18) by PCR 0055616 Method: Polymerase Chain Reaction	Non-Hodgkin lymphoma (NHL) tumor marker
IGH-CCND1 (BCL-1/JH) Translocation, t(11;14) by PCR 0055557 Method: Polymerase Chain Reaction	NHL tumor marker
Chromosome FISH, Interphase 2002298 Method: Fluorescence in situ Hybridization	Monitor disease and identify specific abnormalities suspected clinically Specific FISH probes must be requested – ARUP Oncology FISH Probes menu
BIRC2-MALT1 (AP12-MALT1) Translocation, t(11;18) by RT-PDR 0055691 Method: Reverse Transcription Polymerase Chain Reaction	Tumor marker for leukemia lymphoma phenotyping and mucosa-associated lymphoid tissue lymphoma (MALT)
MYC (8q;24) Gene Rearrangement by FISH 2002345 Method: Fluorescence in situ Hybridization	Burkitt lymphoma tumor marker
IGH-CCND1 Fusion, t(11;14) by FISH 2007226 Method: Fluorescence in situ Hybridization	Lymphoma classification/identification tumor marker
Ki-67 with Interpretation by Immunohistochemistry 2007182 Method: Immunohistochemistry	Lymphoma tumor marker
Octamer Transcription Factor-2 (Oct-2) by Immunohistochemistry 2004061 Method: Immunohistochemistry	Lymphoma tumor marker
CD117 (c-Kit) by Immunohistochemistry 2003806 Method: Immunohistochemistry	Lymphoma tumor marker
CD14 by Immunohistochemistry 2003526 Method: Immunohistochemistry	Lymphoma tumor marker
CD15, Leu M1 by Immunohistochemistry 2003529 Method: Immunohistochemistry	Lymphoma tumor marker
CD20, L26 by Immunohistochemistry 2003532 Method: Immunohistochemistry	Lymphoma tumor marker
CD45 by Immunohistochemistry 2003574 Method: Immunohistochemistry	Marker for diffuse large B-cell lymphoma
CD56 (NCAM) by Immunohistochemistry 2003589 Method: Immunohistochemistry	Lymphoma tumor marker
CD57 by Immunohistochemistry 2003592 Method: Immunohistochemistry	Lymphoma tumor marker
Pax-5 by Immunohistochemistry 2004082 Method: Immunohistochemistry	Lymphoma tumor marker
BCL-6 by Immunohistochemistry 2003457 Method: Immunohistochemistry	Lymphoma tumor marker
Anaplastic Lymphoma Kinase 1 (ALK-1) by Immunohistochemistry 2003439 Method: Immunohistochemistry	Lymphoma tumor marker
Cyclin D1, SP4 by Immunohistochemistry 2003842 Method: Immunohistochemistry	Lymphoma tumor marker
MUM1/IRF4 by Immunohistochemistry 2003975 Method: Immunohistochemistry	Lymphoma tumor marker
CD23 by Immunohistochemistry 2003541 Method: Immunohistochemistry	Lymphoma tumor marker
CD10 (CALLA) by Immunohistochemistry 2003523 Method: Immunohistochemistry	Lymphoma tumor marker
CD8 by Immunohistochemistry 2003520 Method: Immunohistochemistry	Lymphoma tumor marker
CD5 by Immunohistochemistry 2003514 Method: Immunohistochemistry	Lymphoma tumor marker
CD7 by Immunohistochemistry 2003517 Method: Immunohistochemistry	Lymphoma tumor marker
BF-1 by Immunohistochemistry 2003466 Method: Immunohistochemistry	Lymphoma tumor marker
B Cell Specific Octamer Binding Protein-1 (BOB-1) by Immunohistochemistry 2003442 Method: Immunohistochemistry	Lymphoma tumor marker
CD2 by Immunohistochemistry 2003505 Method: Immunohistochemistry	Lymphoma tumor marker
CD3 by Immunohistochemistry 2003508 Method: Immunohistochemistry	Lymphoma tumor marker
CD4 by Immunohistochemistry 2003511 Method: Immunohistochemistry	Lymphoma tumor marker
CD19 by Immunohistochemistry 2005114 Method: Immunohistochemistry	B-cell lymphoma tumor marker
CD138 (Syndecan-1) by Immunohistochemistry 2003812 Method: Immunohistochemistry	Lymphoma tumor marker
T-cell Intracytoplasmic Antigen (TIA-1) by Immunohistochemistry 2004148 Method: Immunohistochemistry	Lymphoma tumor marker
Epstein-Barr Virus (EBV) By in situ Hybridization, Paraffin 2002902 Method: In situ Hybridization	Lymphoma tumor marker

Leukemia

Test Name and Number	Comments
Chromosome FISH, CLL Panel 2002295 Method: Fluorescence in situ Hybridization	Chronic lymphocytic leukemia (CLL) tumor marker
Chromosome FISH, Interphase 2002298 Method: Fluorescence in situ Hybridization	Monitor disease and identify specific abnormalities suspected clinically Specific FISH probes must be requested – ARUP Oncology FISH Probes menu
TCF3-PBX1 (E2A-PBX1) Translocation, t(1;19) by RT-PCR 0055346 Method: Reverse Transcription Polymerase Chain Reaction/Polymerase Chain Reaction	Acute lymphocytic leukemia (ALL) tumor marker
ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21) by RT-PCR 0056008 Method: Reverse Transcription Polymerase Chain Reaction	AML tumor marker
RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) by RT-PCR 0050444 Method: Reverse Transcription Polymerase Chain Reaction	Acute myelogenous leukemia (AML) tumor marker
CBFB-MYH11, inv(16) by RT-PCR 0092209 Method: Reverse Transcription Polymerase Chain Reaction	AML tumor marker
PML/RARα FISH 2002363 Method: Fluorescence in situ Hybridization	AML tumor marker
ZAP-70 Analysis by Flow Cytometry 0092392 Method: Flow Cytometry	AML tumor marker
BCR-ABL1 Kinase Domain Mutation Analysis 0040138 Method: Polymerase Chain Reaction/Sequencing	Tumor marker to monitor drug therapy for CML and ALL Detects >90% of mutations that may lead to imatinib resistance
BCR-ABL1, Major (p210), Quantitative 2005017 Method: Reverse Transcription/Quantitative Polymerase Chain Reaction	Tumor marker for CML and ALL therapy
BCR-ABL1, Minor (p190), Quantitative 2005016 Method: Reverse Transcription/Quantitative Polymerase Chain Reaction	Tumor marker for CML and ALL therapy
BCR-ABL1, T315I Mutation Detection, Quantitative 2004924 Method: Reverse Transcription Polymerase Chain Reaction/Pyrosequencing	Tumor marker for CML and ALL therapy
BCR-ABL1, Major (p210), Quantitative 2005010 Method: Reverse Transcription Polymerase Chain Reaction	Tumor marker for CML and ALL therapy
PIK3CA Mutation Detection 2004510 Method: Polymerase Chain Reaction/Pyrosequencing	Leukemia tumor marker
CD117 (c-Kit) by Immunohistochemistry 2003806 Method: Immunohistochemistry	Leukemia tumor marker
CD14 by Immunohistochemistry 2003526 Method: Immunohistochemistry	Leukemia tumor marker
CD15, Leu M1 by Immunohistochemistry 2003529 Method: Immunohistochemistry	Leukemia tumor marker
CD19 by Immunohistochemistry 2005114 Method: Immunohistochemistry	B-cell leukemia tumor marker
CD20, L26 by Immunohistochemistry 2003532 Method: Immunohistochemistry	Leukemia tumor marker
CD33 by Immunohistochemistry 2003553 Method: Immunohistochemistry	AML tumor marker
CD56 (NCAM) by Immunohistochemistry 2003589 Method: Immunohistochemistry	Leukemia tumor marker
Wilms Tumor (WT-1), N-terminus by Immunohistochemistry 2004184 Method: Immunohistochemistry	Leukemia tumor marker
Pax-5 by Immunohistochemistry 2004082 Method: Immunohistochemistry	Leukemia tumor marker
CD10 (CALLA) by Immunohistochemistry 2003523 Method: Immunohistochemistry	Leukemia tumor marker
Cyclin D1, SP4 by Immunohistochemistry 2003842 Method: Immunohistochemistry	Leukemia tumor marker
CD23 by Immunohistochemistry 2003541 Method: Immunohistochemistry	Leukemia tumor marker
CD2 by Immunohistochemistry 2003505 Method: Immunohistochemistry	Leukemia tumor marker
CD3 by Immunohistochemistry 2003508 Method: Immunohistochemistry	Leukemia tumor marker
CD5 by Immunohistochemistry 2003514 Method: Immunohistochemistry	Leukemia tumor marker
CD57 by Immunohistochemistry 2003592 Method: Immunohistochemistry	Leukemia tumor marker
BCL-6 by Immunohistochemistry 2003457 Method: Immunohistochemistry	Leukemia tumor marker
CD79A by Immunohistochemistry 2003800 Method: Immunohistochemistry	Leukemia tumor marker
TdT by Immunohistochemistry 2004142 Method: Immunohistochemistry	Leukemia tumor marker
Epstein-Barr Virus (EBV) By in situ Hybridization, Paraffin 2002902 Method: In situ Hybridization	Leukemia tumor marker

Myeloproliferative Neoplasms

Test Name and Number	Comments
JAK2 Gene, V617F Mutation, Quantitation 0040168 Method: Polymerase Chain Reaction	Myeloproliferative neoplasms (MPN) tumor marker
JAK2 Gene, V617F Mutation, Qualitative 0051245 Method: Polymerase Chain Reaction	MPN tumor marker
JAK2 Exon 12 Mutation Analysis by PCR 2002357 Method: Polymerase Chain Reaction	MPN tumor marker

Childhood Tumors

Test Name and Number	Comments
LSI MYC t(8q;24) by FISH 2002345 Method: Fluorescence in situ Hybridization	Burkitt lymphoma tumor marker
MLL-AFF1 (MLL-AF4) Translocation, t(4;11) by RT-PCR 0050446 Method: Reverse Transcription Polymerase Chain Reaction	Infant leukemia tumor marker
Neuron Specific Enolase 0098198 Method: Enzyme-Linked Immunosorbent Assay	Marker for germ cell tumors
Catecholamines Fractionated by LC-MS/MS, Urine Free 0080407 Method: Tandem Mass Spectometry	Neuroblastoma (childhood tumors) tumor marker
Homovanillic Acid (HVA), Urine 0080422 Method: High Performance Liquid Chromatography	Neuroblastoma (childhood tumors) tumor marker
MYCN (N-MYC) Gene Amplification by FISH 2007227 Method: Fluorescence in situ Hybridization	Neuroblastoma (childhood tumors) tumor marker
Vanillylmandelic Acid (VMA) & Homovanillic Acid (HVA), Urine 0080470 Method: High Performance Liquid Chromatography	Neuroblastoma (childhood tumors) tumor marker
Chromosome FISH, Interphase 2002298 Method: Fluorescence in situ Hybridization	Monitor disease and identify specific abnormalities suspected clinically Specific FISH probes must be requested – ARUP Oncology FISH Probes menu

Skin

Test Name and Number	Comments
S-100B Protein, Serum 2001766 Method: Enzyme-Linked Immunosorbent Assay	Monitor treatment and determine prognosis in patients with melanoma
NRAS Mutation Detection by Pyrosequencing 2003123 Method: Polymerase Chain Reaction/Pyrosequencing	Use in metastatic tumors to predict response to EGFR-directed therapy
BRAF V600E Mutation Detection by PCR 2002498 Method: Polymerase Chain Reaction/Fluorescence Monitoring	Predict response to EGFR-directed therapy
KIT Mutations, Melanoma 2002695 Method: Polymerase Chain Reaction/High Resolution Melt Analysis	Predict response to EGFR-directed therapy
CD117 (c-Kit) by Immunohistochemistry 2003806 Method: Immunohistochemistry	Melanoma tumor marker
CD56 (NCAM) by Immunohistochemistry 2003589 Method: Immunohistochemistry	Melanoma tumor marker
Melan A by Immunohistochemistry 2003996 Method: Immunohistochemistry	Melanoma tumor marker
S-100 Protein by Immunohistochemistry 2004127 Method: Immunohistochemistry	Melanoma tumor marker
Melanoma Antibody, HMB45 by Immunohistochemistry 2003935 Method: Immunohistochemistry	Melanoma tumor marker
Human Chorionic Gonadotropin  (Beta-hCG) by Immunohistochemistry 2003920 Method: Immunohistochemistry	Melanoma tumor marker

Head & Neck

Test Name and Number	Comments
Squamous Cell Carcinoma Antigen, Serum 0081054 Method: Enzyme-Linked Immunosorbent Assay	Tumor marker for NSCLC, head and neck cancer - squamous cell carcinoma (SCC)
Cytokeratin 19 Fragment (CYFRA 21-1), Serum 0081344 Method: Enzyme-Linked Immunosorbent Assay	Squamous cell cancer tumor marker
Human Papillomavirus (HPV) High Risk in situ Hybridization, Paraffin 2002899 Method: In situ Hybridization	Head and neck cancer marker
Epstein-Barr Virus (EBV) by in situ Hybridization, Paraffin 2002902 Method: In situ Hybridization	Head and neck cancer marker
Cytokeratin 19 (CK 19) by Immunohistochemistry 2003845 Method: Immunohistochemistry	Head and neck cancer marker
CD68, KP1 by Immunohistochemistry 2003598 Method: Immunohistochemistry	Head and neck cancer marker

Thyroid/Parathyroid

Test Name and Number	Comments
Thyroglobulin, Serum or Plasma 2006685 Method: Chemiluminescent Immunoassay	Thyroid cancer tumor marker
Thyroglobulin Antibody 0050105 Method: Chemiluminescent Immunoassay	Thyroid tumor marker
BRAF V600E Mutation Detection by PCR 2002498 Method: Polymerase Chain Reaction/Fluorescence Monitoring	Thyroid cancer tumor marker
Thyroglobulin, Fine Needle Aspiration (FNA) 0020753 Method: Chemiluminescent Immunoassay	Thyroid tumor marker
Parathyroid Hormone, Intact with Calcium 0070172 Method: Electrochemiluminescent Immunoassay	Parathyroid cancer tumor marker
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Gene Mutations by Sequencing 0051390 Method: Polymerase Chain Reaction/Sequencing	Hereditary thyroid cancer genetic marker
CDX2 by Immunohistochemistry 2003821 Method: Immunohistochemistry	Thyroid/parathyroid tumor marker
Parathyroid Hormone (PTH) by Immunohistochemistry 2004118 Method: Immunohistochemistry	Parathyroid tumor marker
Muc-1 by Immunohistochemistry 2004002 Method: Immunohistochemistry	Thyroid tumor marker
Muc-2 by Immunohistochemistry 2004005 Method: Immunohistochemistry	Thyroid tumor marker
Muc-4 by Immunohistochemistry 2004008 Method: Immunohistochemistry	Thyroid tumor marker
Thyroglobulin by Immunohistochemistry 2004145 Method: Immunohistochemistry	Thyroid tumor marker
Thyroid Transcription Factor (TTF-1) by Immunohistochemistry 2004166 Method: Immunohistochemistry	Thyroid tumor marker
p27 (Kip1) by Immunohistochemistry 2004070 Method: Immunohistochemistry	Thyroid tumor marker
Calcitonin by Immunohistochemistry 2003481 Method: Immunohistochemistry	Parathyroid tumor marker